BMS-986497 (ORM-6151)
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Near Add Your Location
Sorting 6 by
Center of Excellence
Herbert Irving Comprehensive Cancer Center (Columbia University)
Columbia University Medical Center
New York, NY
- Accepting patients
Center of Excellence
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack Meridian Health
Hackensack, NJ
- Accepting patients
Center of Excellence
- Accepting patients
- Accepting patients
Center of Excellence
Massachusetts General Hospital
Boston, MA
- Accepting patients
Center of Excellence
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL
- Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.